Silencing of human RPN2 also decreases drug resistant breast tumor and esophageal squamous cell carcinoma growth [50,51], indicating that RPN2 may function in cell division and be an important cancer therapeutic target. Here, RPN2 is linked to esophageal squamous cell carcinoma.